Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
27-30 April, 2026
Not Confirmed
Not Confirmed
27-29 April, 2026
Stanford Drug Discover...Stanford Drug Discovery Symposium
Not Confirmed
Not Confirmed
27-28 April, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
27-30 April, 2026
Industry Trade Show
Not Confirmed
27-29 April, 2026
Stanford Drug Discover...Stanford Drug Discovery Symposium
Industry Trade Show
Not Confirmed
27-28 April, 2026
Digital content

13 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/13/3272882/24180/en/Celldex-to-Present-at-Upcoming-Investor-Conference.html

06 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/06/3268530/24180/en/Celldex-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html

01 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/01/3266968/24180/en/Celldex-Announces-Proposed-Public-Offering-of-Common-Stock.html

27 Mar 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/03/27/3263841/24180/en/Celldex-Presents-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-and-Phase-2-Cold-Urticaria-and-Symptomatic-Dermographism-Studies-Demonstrating-Rapid-Profound-and-Durable-.html

27 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/27/3246759/24180/en/Celldex-Presents-Additional-Positive-Data-from-Phase-2-Chronic-Spontaneous-Urticaria-CSU-and-Phase-2-Cold-Urticaria-ColdU-and-Symptomatic-Dermographism-SD-Studies-Further-Demonstra.html

25 Feb 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/02/25/3244485/24180/en/Celldex-Completes-Enrollment-in-Global-Phase-3-Studies-EMBARQ-CSU1-and-EMBARQ-CSU2-of-Barzolvolimab-in-Chronic-Spontaneous-Urticaria.html
ABOUT THIS PAGE